


## ATR-IN-4

<b>Cat. No.:</b>	HY-145312
<b>CAS No.:</b>	2574545-45-0
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>20</sub> N <sub>8</sub> O
<b>Molecular Weight:</b>	364.4
<b>Target:</b>	ATM/ATR
<b>Pathway:</b>	Cell Cycle/DNA Damage; PI3K/Akt/mTOR
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 25 mg/mL (68.61 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>2.7442 mL</td> <td>13.7212 mL</td> <td>27.4424 mL</td> </tr> <tr> <td>5 mM</td> <td>0.5488 mL</td> <td>2.7442 mL</td> <td>5.4885 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2744 mL</td> <td>1.3721 mL</td> <td>2.7442 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	2.7442 mL	13.7212 mL	27.4424 mL	5 mM	0.5488 mL	2.7442 mL	5.4885 mL	10 mM	0.2744 mL	1.3721 mL	2.7442 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	2.7442 mL	13.7212 mL	27.4424 mL																		
	5 mM	0.5488 mL	2.7442 mL	5.4885 mL																		
	10 mM	0.2744 mL	1.3721 mL	2.7442 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (6.86 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.86 mM); Clear solution</li> </ol>																					

## BIOLOGICAL ACTIVITY

<b>Description</b>	ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC <sub>50</sub> s of 130.9 nM and 41.33 nM, respectively. (Patent CN112142744A, compound 13) <sup>[1]</sup> .
--------------------	---

## REFERENCES

[1]. Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and uses thereof. CN112142744A.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA